AAAAAA
Results:
1-11
|
Results: 11
Authors:
Judson, I
Radford, JA
Harris, M
Blay, JY
van Hoesel, Q
le Cesne, A
van Oosterom, AT
Clemons, MJ
Kamby, C
Hermans, C
Whittaker, J
di Paola, ED
Verweij, J
Nielsen, S
Citation: I. Judson et al., Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL (R)/CAELYX (R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group, EUR J CANC, 37(7), 2001, pp. 870-877
Authors:
Sengelov, L
Kamby, C
von der Maase, H
Citation: L. Sengelov et al., Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years, EUR UROL, 39(6), 2001, pp. 634-642
Authors:
Sengelov, L
Frolich, S
Psych, M
Kamby, C
Jensen, NH
Steven, K
Citation: L. Sengelov et al., The functional and psychosocial status of patients with disseminated bladder cancer, UROL ONCOL, 5(1), 2000, pp. 20-24
Authors:
Sengelov, L
Kamby, C
Geertsen, F
Andersen, LJ
von der Maase, H
Citation: L. Sengelov et al., Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer, CANC CHEMOT, 46(5), 2000, pp. 357-364
Authors:
Rose, C
Kamby, C
Mouridsen, HT
Andersson, M
Bastholt, L
Moller, KA
Andersen, J
Munkholm, P
Dombernowsky, P
Christensen, IJ
Citation: C. Rose et al., Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer - A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone and tamoxifen plus fluoxymesterone in women above 65 years of age, BREAST CANC, 61(2), 2000, pp. 103-110
Authors:
Sengelov, L
Christensen, M
von der Maase, H
Horn, T
Marcussen, N
Kamby, C
Orntoft, T
Citation: L. Sengelov et al., Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelialcancer and lack of relation to chemotherapy response and outcome, CANC GENET, 123(2), 2000, pp. 109-113
Authors:
Andersson, M
Kamby, C
Jensen, MB
Mouridsen, H
Ejlertsen, B
Dombernowsky, P
Rose, C
Cold, S
Overgaard, M
Andersen, J
Kjaer, M
Citation: M. Andersson et al., Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B trial, EUR J CANC, 35(12), 1999, pp. 1659-1666
Authors:
Kamby, C
Sengelov, L
Citation: C. Kamby et L. Sengelov, Survival and pattern of failure following locoregional recurrence of breast cancer, CL ONCOL-UK, 11(3), 1999, pp. 156-163
Authors:
Overgaard, M
Jensen, MB
Overgaard, J
Hansen, PS
Rose, C
Andersson, M
Kamby, C
Kjaer, M
Gadeberg, CC
Rasmussen, BB
Blichert-Toft, M
Mouridsen, HT
Citation: M. Overgaard et al., Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial, LANCET, 353(9165), 1999, pp. 1641-1648
Authors:
Sengelov, L
von der Maase, H
Kamby, C
Jensen, LI
Rasmussen, F
Horn, T
Nielsen, SL
Steven, K
Citation: L. Sengelov et al., Assessment of patients with metastatic transitional cell carcinoma of the urinary tract, J UROL, 162(2), 1999, pp. 343-346
Authors:
Christensen, TB
Engbaek, F
Marqversen, J
Nielsen, SI
Kamby, C
von der Maase, H
Citation: Tb. Christensen et al., I-125-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer, BR J CANC, 80(10), 1999, pp. 1577-1581
Risultati:
1-11
|